

RESEARCH

Open Access



# Disulfide isomerase ERp57 improves the stability and immunogenicity of H3N2 influenza virus hemagglutinin

Jialing Wu<sup>1,2</sup>, Yang Wang<sup>1</sup>, Ying Wei<sup>1</sup>, Zhichao Xu<sup>1</sup>, Xin Tan<sup>1</sup>, Zhihui Wu<sup>1</sup>, Jing Zheng<sup>1</sup>, George Dacai Liu<sup>3</sup>, Yongchang Cao<sup>1</sup> and Chunyi Xue<sup>1\*</sup>

## Abstract

**Background:** Hemagglutinin (HA), as the surface immunogenic protein, is the most important component of influenza viruses. Previous studies showed that the stability of HA was significant for HA's immunogenicity, and many efforts have been made to stabilize the expressed HA proteins.

**Methods:** In this study, the protein disulfide isomerases (PDIs) were investigated for the ability to improve the stability of HA protein. Two members of the PDIs family, PDI and ERp57, were over-expressed or down-expressed in 293 T cells. The expression of H3 HA and PDIs were investigated by real-time qPCR, western-blot, immunofluorescence assay, and flow cytometry. The stability of HA was investigated by western-blot under non-reducing condition. Moreover, BALB/c mice were immunized subcutaneously twice with the vaccine that contained HA proteins from the ERp57-overexpressed and conventional 293 T cells respectively to investigate the impact of ERp57 on the immunogenicity of H3N2 HA.

**Results:** The percentage of the disulfide-bonded HA trimers increased significantly in the PDIs-overexpressed 293 T cells, and ERp57 was more valid to the stability of HA than PDI. The knockdown of ERp57 by small interfering RNA significantly decreased the percentage of the disulfide-bonded HA trimers. HA proteins from ERp57-overexpressed 293 T cells stimulated the mice to generate significantly higher HA-specific IgG against H1N1 and H3N2 viruses than those from the conventional cells. The mice receiving H3 HA from ERp57-overexpressed 293 T cells showed the better resistance against H1N1 viruses and the higher survival rate than the mice receiving H3 HA from the conventional cells.

**Conclusion:** ERp57 could improve the stability and immunogenicity of H3N2 HA.

**Keywords:** Hemagglutinin, Protein disulfide isomerase, ERp57, Stability, Immunogenicity

## Background

The infection of the influenza virus is still one of the main reasons which cause human illness and death [1–3]. There are four severe outbreaks of influenza, the Spanish influenza in 1918 which was caused by H1N1, the Asian influenza in 1958 caused by H2N2, the Hong Kong influenza

in 1968 caused by H3N2 and the Mexico influenza in 2009 caused by H1N1. Today the prevention of influenza virus is still a big challenge because of its high mutability [3, 4]. Vaccine immunization is the most important way to prevent from influenza at present, and vaccines are prepared every year based on the predicted influenza virus strains [2–5]. It will lead to a pandemic if the prediction is inaccurate [4]. So broad-spectrum vaccines with wider protection against influenza viruses have become a hot topic in recent years.

\* Correspondence: [xuechy@mail.sysu.edu.cn](mailto:xuechy@mail.sysu.edu.cn)

<sup>1</sup>State Key Laboratory of Biocontrol, School of Life Science, Sun Yat-sen University, Higher Education Mega Center, Guangzhou 510006, China  
Full list of author information is available at the end of the article



© The Author(s). 2020 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Hemagglutinin (HA), as the homo-trimeric glycoprotein of the influenza virus envelope, contains an extracellular, transmembrane and intracellular region [6]. HA plays an important role in infection by mediating virus entry into the host cell and fusion between viral and cellular target membrane and is used as a crucial component of the broad-spectrum vaccine [6–8]. There are many strategies in the research of broad-spectrum HA vaccines, such as changing the ways of immunization and transforming HA proteins [3, 4, 9, 10]. The discovery of several broadly reactive antibodies against the HA head and stalk domain was a major milestone towards the development of universal influenza virus vaccine [11–13]. Previous studies showed that HAs from H3N2 have two conserved cysteines, in the 540 and 544 sites of the transmembrane domain, which were significant for the stability of HA trimer [14, 15]. The stable structure of HA trimer depended on disulfide bonds formed between cysteines of the HA monomer and was important for HA's immunogenicity [14]. The introduction of a Cys-Phe-Leu-Leu-Cys (CFLLC) minidomain into the transmembrane domain of H1, H5 and H9 HA proteins by replacing with H3 HA transmembrane increased higher antibodies in mice than wild type [16–22]. Accordingly, the protein family of protein disulfide isomerases (PDIs) which assist the formation of disulfide bonds [23] were investigated for the ability to improve the stability of HA proteins in this study.

PDIs are a kind of enzyme that catalyzes redox reaction in the endoplasmic reticulum (ER), which can help the formation of disulfide bonds between cysteines and the correct folding of proteins [24–26]. There are more than 20 members of this protein family in mammals [23, 27]. Cells cannot survive if the important members are knocked out, like PDI-one of members [28]. In this study, we chose two members of the PDIs family: PDI and ERp57. PDI is one of the highest content proteins in the ER [25]. ERp57, unlike most PDI family members, does not contain a C-terminal ER retention motif capable of effectively limiting localization to the ER lumen and has been found in many different subcellular locations [29]. Available evidences indicated multiple distinct biological functions of ERp57, such as mediation of protein folding and Ca<sup>2+</sup> balance in ER, delivery of apoptotic signaling in the mitochondria, and potential regulation of gene expression in the nucleus [29]. ERp57 was proved that it has a crucial role in post-translational reshuffling to the native set of HA disulfides [30].

However, it is unclear whether PDIs can actively improve the stability of the HA structure and whether the mice stimulated by HA with more stable HA trimers could generate the higher level of antibodies. In this study, we overexpressed two members of PDIs family: PDI and ERp57 to study their effect on the stability of HA, which results were further confirmed by the knock-down expression. Moreover, we investigated whether

HA proteins from ERp57-overexpressed 293 T cells could stimulate the mice to produce higher antibodies than those from the conventional cells. Our results showed that ERp57 could improve the stability and immunogenicity of H3N2 HA, which may help the development of vaccine against influenza against pandemics.

## Materials and methods

### Cell lines, viruses, and mice

Human embryonic kidney cells (293 T) kept by our laboratory were cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (Thermo Scientific), penicillin (100 units/ml), and streptomycin (100 µg/ml) at 37 °C with 5% CO<sub>2</sub>.

Influenza virus strains A/swine/Guangdong/01/1998(H3N2), A/chicken/Guangdong/32/2007(H9N2) and A/Puerto Rico/8/1934(H1N1) were kept by our laboratory.

BALB/c mice were bred at the Laboratory Animal Center of Sun Yat-Sen University under the pathogen-free conditions. Six-eight-week-old female mice were randomly assigned to treatment or control groups in the experiment.

### Plasmid construction

RNA of H3N2 viruses (GenBank accession no. FJ830855.1) and 293 T cells were extracted using HiPure Viral RNA/DNA Kit (Magen) and TRIzol (Invitrogen) respectively. cDNA was prepared using PrimeScript™ II 1st Strand cDNA Synthesis Kit (TAKARA). H3 HA was amplified from H3N2 viruses using the following primers: H3 HA-Forward (*Kpn* I) 5'-GGGGTACCTAATTCTATCAACCATGAAGACTAT-3' and H3 HA-Reverse (*Xho* I) 5'-CCGCTCGAGAGGGTGTTTTTAATTACTAATATACTCA-3'. PDI and ERp57 segments were amplified from 293 T cells using the following primers: PDI-Forward (*Hind* III) 5'-CCCAAGCTTCCAGGATTTATAAAGGCGAGGC-3', PDI-Reverse (*Not* I) 5'-CGGAATTCCGGGTCTGGCTTTGCGTAT-3', ERp57-Forward (*Hind* III) 5'-CCCAAGCTTCGCAAGCAGCGGGTTAGT-3' and ERp57-Reverse (*Bam*H I) 5'-CGGGATCCTCCTAGTCTCCCAATGGTT-3'. H3 HA, PDI and ERp57 PCR products were cloned into pcDNA3.1(+) (Invitrogen) respectively. All clones were verified by sequencing (Thermo).

### Expression of HA proteins with PDIs overexpression in 293 T cells

To investigate whether PDIs can improve the stability of HA, cells were transfected with 2 µg of H3 HA and PDI (or ERp57) plasmids in a 6-well plate, using PEI-MAX (Polyscience) according to the manufacturer's protocol. Briefly, 293 T cells were seeded in a 6-well plate at a density of 1 × 10<sup>5</sup> cells/mL and cultured until the cells reached approximately 80–90% confluence. Purified

plasmids and PEI-MAX (Polyscience) were incubated in the opti-MEM at the concentration ratio of 1:4 respectively at room temperature for 5 min and then mixed to incubate at room temperature for 20 min. The mixture was added to 293 T cells to incubate at 37 °C for 8 h with 5% CO<sub>2</sub> before the replacement with the fresh medium. After 48 h incubation at 37 °C with 5% CO<sub>2</sub>, 293 T cells were collected.

#### Expression of HA proteins with ERp57 RNA depletion by small interfering RNA (siRNA)

To downregulate ERp57 expression, 293 T cells were transfected with 200 nM siRNA against ERp57 (5'-GGA-CAAGACTGTGGCATAT-3', RIBOBIO) using lipo2000 (Invitrogen) according to the manufacturer's instructions. Briefly, 293 T cells were seeded in a 12-well plate at a density of 1 × 10<sup>5</sup> cells/mL and cultured until the cells reached approximately 50% confluence. siRNA and lipo2000 at the concentration ratio of 1:2 were incubated in the opti-MEM respectively at room temperature for 5 min and then mixed to incubate at room temperature for 20 min. After the mixture was added to 293 T cells to incubate at 37 °C for 24 h with 5% CO<sub>2</sub>, 293 T cells were transfected with 1 µg H3 HA plasmids in a 12-well plate using PEI-MAX. After incubation for 48 h at 37 °C with 5% CO<sub>2</sub>, 293 T cells were collected.

#### Characterization of H3 HA and PDIs expression

To confirm and characterize H3 HA and PDIs expression, real-time qPCR, western-blot, immunofluorescence assay, and flow cytometry were carried out.

For real-time qPCR, total RNA was extracted from 293 T cells with TRIzol, and treated with DNase I. cDNA was synthesized by reverse transcription using RT-PCR kit (TaKaRa, Dalian). Real-time qPCR was performed with the following primers (ERp57-Forward 5'-TCACGGACGACAACCTTCGAG-3', ERp57-Reverse 5'-GTTGGCAGTGCAATCAACCT-3', GAPDH-Forward 5'-AACGGATTTGGTCGTATTG-3', GAPDH-Reverse 5'-GGAAGATGGTGATGGGATT-3') using LightCycler 480 SYBR Green I Master (Roche) according to the manufacturer's protocol. Briefly, PCR was performed in a 20 µL volume containing 100 ng of cDNA, 10 µL of 2 × LightCycler 480 SYBR Green I Master, and a 0.2 µM of each gene-specific primer. The thermal cycling parameters were referring to the manufacturer's protocol: 95 °C for 5 min, 40–45 cycles of 95 °C for 10 s, 58 °C for 20 s, 72 °C for 30 s, 1 cycles of 95 °C for 5 s, 65 °C for 1 min, 97 °C for continuous, and 40 °C for 10 s. The final cycle was set to obtain a melting curve for the PCR products to determine the specificity of the amplification. The GAPDH gene was utilized as the reference gene. Expression levels of genes were calculated relative to the expression of the GAPDH gene and expressed as fold increase or decrease relative to the control samples.

For western-blot, cells were collected and lysed with RIPA lysis buffer. The protein concentration in samples was quantified by BCA assay (Thermo Fisher Scientific). And then samples were heated at 100 °C for 10 min in the loading buffer with (for reducing SDS-PAGE) or without (for non-reducing SDS-PAGE) 1% β-mercaptoethanol. Total proteins were separated by 10% SDS polyacrylamide gels, electrophoretically transferred to polyvinylidene difluoride membrane (Millipore, 45 µm), and then detected with mouse polyclonal anti-H3 HA serum (kept by our lab), rabbit polyclonal anti-PDI antibody (Abcam, ab3672), mouse monoclonal anti-ERp57 antibody (Abcam, ab13506) respectively, followed with the corresponding secondary antibody and the commercial ECL kit (Fdbio science). Protein loads were estimated using murine anti-β-actin mAb (Abmart, M20010). The band intensity was quantified using ImageJ software.

For immunofluorescence assay, after 48 h transfection, cells were collected and fixed in 4% phosphate-buffered paraformaldehyde at room temperature for 10–15 min, permeabilized, blocked, and reacted with primary antibodies (same as those used in western-blot) and mouse-specific Cy3-conjugated secondary antibody/rabbit-specific FITC-conjugated secondary antibody (PTG). Cell nuclei were stained with 4'-6'-diamidino-2-phenylindole (DAPI) (Sigma-Aldrich) and visually inspected by epifluorescence light microscopy before the acquisition of representative areas by confocal microscopy. Stained sections were analyzed by a scanning confocal microscopy (Leica TCS-SP5).

For flow cytometry, cells were collected in a single-cell suspension with the 0.05% Trypsin-EDTA digestion, fixed in 70% ethanol in the ice for 30 min, permeabilized, blocked, and reacted with primary antibodies (same as those used in western-blot) and secondary antibodies (same as those used in immunofluorescence assay). Flow cytometric analyses were performed using FACS Calibur (BD biosciences), and data were analyzed using FlowJo software.

#### Purification of H3 HA proteins

H3 HA proteins were purified by using ion-exchange chromatography as described previously [31]. Briefly, samples were lysed in Buffer A (20 mM sodium phosphate, 1.0 mM EDTA, 0.01% Tergitol-NP9, 5% glycerol, pH 5.89) in the ice for 30 min and centrifugated at 10,000×g for 25 min. The supernatant was loaded on tandem Q/SP columns and the columns were disconnected after washed by buffer A. HA was eluted from the SP column with buffer B (20 mM sodium phosphate, 0.03% Tergitol-NP9, 5% glycerol, pH 7.02) and buffer C (20 mM sodium phosphate, 150 mM NaCl, 0.03% Tergitol-NP9, 5% glycerol, pH 7.02) consecutively, but mostly in the buffer C. The eluted HA proteins in buffer C was further purified and concentrated by ultrafiltration with

a stirred cell using a 100 kDa MWCO regenerated cellulose membrane (Millipore).

#### Mouse immunization and challenge

Six- to eight-week-old female BALB/c mice ( $n = 5$ ) were vaccinated subcutaneously twice at the interval of 2 weeks with 10  $\mu\text{g}$  of H3 HA expressed in ERp57-overexpressed 293 T cells (named as H3 HA/ERp57) or in the conventional 293 T cells (named as H3 HA) in a 100  $\mu\text{l}$  volume with oil emulsion containing 2% aluminum stearate, 2% Tween-80 and 4% span 80. Blood samples were collected from the tail vein of each mouse 2 weeks after the second immunization. After one more week, mice were challenged intranasally with 40  $\mu\text{L}$  of mouse-adapted wild-type H1N1 viruses at a dose of  $3 \times 50\%$  mice lethal dose ( $\text{MLD}_{50}$ ). After the challenge, the mice were monitored for 14 days for survival and weight loss daily. The mice that lost 25% or more of their initial body weight were scored dead and euthanized.

#### Hemagglutination inhibition (HI) assay

HI assay was performed as described before [14]. Briefly, four HA units of inactivated H1N1, H3N2, and H9N2 viruses were used. Each serum sample was treated with receptor destroying enzyme (RDE, Denka Seiken) at 37 °C overnight, then incubated at 56 °C for 1 h immediately for the hydrolysis of RDE. Serum samples were diluted 10-fold initially then 2-fold continuously for ten times. The highest dilution of serum samples that inhibits hemagglutination was defined as the HI titers.

#### Enzyme-linked immunosorbent assay (ELISA) for testing HA-specific IgG antibodies

HA specific IgG antibody titers were tested by ELISA as previously described [32]. Briefly, inactivated H1N1, H3N2, and H9N2 purified viruses at the concentration of 1  $\mu\text{g}/\text{mL}$  of HA1 were coated at 4 °C overnight, incubated with serial dilutions of each serum sample at 37 °C for 1 h, and detected by HRP-conjugated goat anti-mouse IgG polyclonal antibodies (Proteintech). The optical densities were detected at 450 nm ( $\text{OD}_{450}$ ) using ELISA plate reader (Bio-Tek Instruments). The antibody titer was determined as the reciprocal of the highest dilution of three-fold  $\text{OD}_{450}$  reading of negative control.

#### Statistics analysis

All statistical analyses were performed using Graphpad Prism software (Graphpad). Statistical analyses were performed using one or two-way ANOVA. Data are shown as mean  $\pm$  SD or mean  $\pm$  SEM as indicated in the figure legends. Significance was assumed with \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , \*\*\*\* $p < 0.0001$ .

## Results

### Overexpression of PDIs did not impact the expression and characterization of HA proteins in 293 T cells


To investigate the impact of the overexpression of PDIs on the expression of H3 HA proteins, the recombinant H3 HA and PDIs plasmids were co-transfected into 293 T cells. PDI and ERp57 proteins were successfully overexpressed in 293 T cells which was confirmed by western-blot (Fig. 1a and b) and immunofluorescence assay (Fig. 1c and d). The percentage of cells showing overexpression was 54.9% for PDI and 48.9% for ERp57 (Fig. 1c and d). PDI and ERp57 were abundant in overexpression groups but sparse in negative-control group. The expression of H3 HA proteins was not affected by the overexpression of PDI and ERp57 in 293 T cells as demonstrated by western-blot (Fig. 2a), immunofluorescence assay (Fig. 2b) and flow cytometry (Fig. 2c).

### HA trimers showed significantly higher stability in PDIs-overexpressed cells than in the conventional 293 T cells

To investigate the stability of HA, the disulfide-bonded HA trimers were detected by western-blot under non-reducing condition (Fig. 3a). The results showed that the proportion of the disulfide-bonded HA trimers in PDIs-overexpressed 293 T cells ( $11.1\% \pm 2.8$  for PDI/HA group,  $22.4\% \pm 5.4$  for ERp57/HA group) was significantly higher than those in the conventional 293 T cells ( $4.0\% \pm 2.3$ ) ( $p < 0.05$ ,  $p < 0.01$ ) (Fig. 3b), which means that HA trimers expressed in the PDIs-overexpressed 293 T cells showed the higher stability than those expressed in the conventional 293 T cells. What's more, the percentage of HA trimers expressed in the ERp57-overexpressed 293 T cells was significantly higher than those in the PDI-overexpressed cells ( $p < 0.05$ ), suggesting ERp57 is more effective to stabilize HA proteins than PDI. Therefore, we selected ERp57 for the following research.

### The percentage of HA trimers significantly descended when the ERp57 expression was knocked down by siRNA

To investigate the stability of HA expressed in the ERp57-downexpressed and conventional 293 T cells, we down-regulated the expression of ERp57 by siRNA. Synthesized siRNA targeting ERp57 efficiently decreased the expression of endogenous ERp57 mRNA (Fig. 4a) and protein (Fig. 4b). The results of western-blot under reducing condition showed that the amount of HA proteins was not significantly different between groups (Fig. 4c). The disulfide-bonded HA trimers were detected by western-blot under non-reducing condition (Fig. 4d), and the results showed the proportion of the disulfide-bonded HA trimers was significantly lower ( $0.1\% \pm 0.3$ ,  $p < 0.01$ ) (Fig. 4e) when ERp57 proteins expressed in a low level, suggesting that ERp57 proteins are important for maintaining the stability of HA.



### H3 HA from ERp57-overexpressed 293 T cells elicited significantly higher HI titers and HA-specific antibodies than H3 HA from the conventional cells

To explore whether or not HA proteins from ERp57-overexpressed 293 T cells show higher immunogenicity, mice were immunized subcutaneously twice with the vaccine H3 HA/ERp57 and H3 HA that contained HA proteins from the ERp57-overexpressed and conventional 293 T cells, respectively. The serum samples were analyzed by HI assay and ELISA.



H3 HA/ERp57 elicited 1.68-fold higher HI titers than H3 HA against H3N2 antigen ( $1004.2 \pm 769.5$  vs  $1688.4 \pm 700.3$ ,  $p = 0.0047$ ). H3 HA/ERp57 elicited HI titers against H1N1 ( $40 \pm 21.9$ ), while H3 HA did not elicit HI titer against H1N1 ( $p < 0.0001$ ). HI titer against H9N2 in H3 HA/ERp57 and H3 HA group were not detected (Fig. 5a).



No matter for the homologous and heterologous antigen, H3 HA/ERp57 elicited higher serum HA-specific

IgG antibody titers than H3 HA. The HA-specific IgG antibody titers of H3 HA and H3 HA/ERp57 did not show statistical difference for the heterologous antigen H9N2 ( $13,324.2 \pm 929.1$  vs  $25,333.3 \pm 6694.4$ ,  $p = 0.1636$ ), while H3 HA/ERp57 elicited significantly higher HA-specific IgG antibody titers than H3 HA for the heterologous antigen H1N1 ( $16,266.0 \pm 2604.4$  vs  $10,435 \pm 910.5$ ,  $p = 0.0221$ ) and homologous antigen H3N2 ( $46,436.7 \pm 24,770.1$  vs  $20,517.5 \pm 3563.7$ ,  $p = 0.0204$ ) (Fig. 5b).

### Mice immunized with H3 HA/ERp57 showed better resistance and higher survival rate against heterologous H1N1 challenge than those immunized with H3 HA

To determine the level of protection against the challenge of the heterologous virus, mice were challenged intranasally with  $3 \times \text{MLD}_{50}$  of mouse-adapted wild-type H1N1 viruses 2 weeks after final immunization and monitored for their weight loss and survival daily for 14





days. Mice immunized with H3 HA/ERp57 showed less weight loss than those immunized with H3 HA till 7 day post-infection (dpi), especially at 6 dpi ( $p = 0.0035$ ) (Fig. 6a), indicating that mice immunized with H3 HA/ERp57 showed the better resistance against H1N1 viruses than those immunized with H3 HA. And mice receiving H3 HA/ERp57 were completely protected against H1N1 challenge while those receiving H3 HA had only 40% survival rate ( $p = 0.0486$ ) (Fig. 6b).


## Discussion

The broad-spectrum vaccine with wider protection against influenza viruses is a hot topic in recent years. HA, as the main ingredient of broad-spectrum vaccine, plays an important role on the improvement for immunogenicity of vaccines [1–3, 33–35]. Many researches showed that the stable structure of HA was crucial for HA's immunogenicity [14, 15, 36]. However, how to improve HA stability effectively and safely still needs more researches. Here, we uncovered a key role of PDIs in the improvement of the stability of HA. HAs from overexpressed-PDIs 293 T cells were more stable than those from the conventional cells and could stimulate mice to produce higher HA-specific IgG and HI antibodies against H1N1 and H3N2 viruses.

The research of HA protein, which is related to the immunogenicity and infectivity of the influenza virus, is mainly focused on its structure, function, and application in the vaccine [13, 37, 38]. In order to improve influenza vaccines, many efforts have been made to stabilize the expressed HA proteins, such as fusing HA extracellular domain to the trimerization sequences or introducing a CFLLC minidomain into the transmembrane domain of HA proteins [16, 18, 20, 34, 39–41]. PDIs, one of the most important protein families in cells, catalyze the formation of intra- and inter-molecular

disulfide bonds between cysteines and help the correct folding of proteins [24–26]. ERp57 has been proved to play a crucial role in the post-transcription of HA proteins [30]. In this study, we demonstrated the stability of HAs from the overexpressed-PDIs 293 T cells increased significantly. The expression level of PDI proteins was low in 293 T and CEF cells than in Sf9 and MDCK cells (Fig. S1). CEF cells as the primary cells are difficult to obtain while 293 T cells are often used to express heterologous proteins, so we overexpressed PDIs in 293 T cells to study the effect of PDIs on HA proteins. Overexpression of PDIs did not impact the expression and characterization of HA proteins in 293 T cells as demonstrated by western-blot, immunofluorescence assay, and flow cytometry. HA proteins from PDIs-overexpressed 293 T cells showed a higher proportion of the disulfide-bonded HA trimers than those from the conventional cells, and knockdown of ERp57 by siRNA significantly decreased the percentage of HA trimers, which demonstrated that PDIs can promote the formation efficiency of disulfide bonds of HA proteins and improve the stability of HA in 293 T cells. Furthermore, the proportion of the disulfide-bonded HA trimers from ERp57-overexpressed 293 T cells was significantly higher than PDI-overexpressed cells. The results showed that increased PDI expression favors the stability of HA, suggesting that correct protein folding may be crucial to the stability of the expressed HA proteins in 293 T cells.

Many studies have shown the close correlation of HA stability and immunity. By fusing HA extracellular domain to the trimerization sequences, the stability and immunogenicity of HA proteins have been increased [34, 39–41]. By introducing a CFLLC minidomain into the transmembrane domain of H1, H5, H7 and H9 HA proteins, these HA proteins expressed in insect cells





increased their stability, cross-reactive immunity and protection over their wildtype counterparts [16, 18, 20]. In this study, HA proteins from ERp57-overexpressed 293 T cells stimulated the mice to generate the higher HA-specific IgG against H1N1 and H3N2 viruses than those from the conventional cells. These results demonstrated that HA proteins from ERp57-overexpressed 293 T cells had better immunogenicity than those from the conventional cells. As shown in Fig. 5a, H3 HA/ERp57 elicited 1.68-fold higher HI titers than H3 HA against H3N2 antigen ( $p = 0.0047$ ). H3 HA/ERp57 elicited HI titers against H1N1 while H3 HA did not elicit HI titer against H1N1 ( $p < 0.0001$ ). So, H1N1 was chosen as the challenged strain. Mice immunized with H3 HA/ERp57 showed less body weight loss than those immunized with H3 HA till 7 dpi, especially at 6 dpi ( $p < 0.01$ ), and mice in H3 HA/ERp57 groups were completely protected against H1N1 challenge, while mice in H3 HA groups were only 40% protected. So further studies are necessary to confirm the exact contribution of PDIs to the stability of HA in other influenza viruses or in other frequently-used HA-expressed systems and understand the exact underlying mechanism.

In summary, this study demonstrated PDIs can improve the formation efficiency of the disulfide bonds between HA monomers and increase the stability of HA. Furthermore, HAs from ERp57-overexpressed 293 T cells could stimulate higher HI and IgG antibodies against H1N1 and H3N2 antigens. And mice receiving HAs from ERp57-overexpressed 293 T cells showed the better resistance against H1N1 viruses and higher survival rate than mice receiving HAs from conventional 293 T cells.

## Conclusion

Conclusively, ERp57, a member of the PDIs family, could improve the stability and immunogenicity of H3 HA, which may help the development of vaccine against influenza against pandemics.

## Supplementary information

**Supplementary information** accompanies this paper at <https://doi.org/10.1186/s12985-020-01325-x>.

**Additional file 1: Figure S1.** The expression of PDI in different cell lines.

## Abbreviations

HA: Hemagglutinin; PDI: Protein disulfide isomerases; ER: Endoplasmic reticulum; CFLC: Cys-Phe-Leu-Leu-Cys; IFA: Immunofluorescence assay; MLD<sub>50</sub>: 50% mice lethal dose; HI: Hemagglutination inhibition; ELISA: Enzyme-linked immunosorbent assay; dpi: Day post-infection.

## Acknowledgements

Not applicable.

## Authors' contributions

JW, YW, GDL, YC and CX conceived and designed the experiments; JW, YW, XT and ZW performed the experiments; JW and CX analyzed the data; YW and JZ contributed reagents/materials/analysis tools; JW wrote the paper; ZX revised the paper; CX checked and finalized the manuscript. All authors read and approved the final manuscript.

## Funding

This work was supported by Guangdong Natural Science Foundation (2015A030313095) and Guangdong Science and Technology Plan (2014A050503038).

## Availability of data and materials

Data and materials are available from the corresponding author on reasonable request.

## Ethics approval

The animal experiment was performed in accordance with the guidance of Sun Yat-Sen University Institutional Animal Care and Use Committee.

## Consent for publication

Not applicable.

## Competing interests

All the authors declare that they have no competing interests.

## Author details

<sup>1</sup>State Key Laboratory of Biocontrol, School of Life Science, Sun Yat-sen University, Higher Education Mega Center, Guangzhou 510006, China. <sup>2</sup>Clinical Research Institute, The First People's Hospital of Foshan, Foshan 528000, China. <sup>3</sup>Firstline Biopharmaceuticals Corporation, 12050 167th PL NE, Redmond, WA 98052, USA.

Received: 13 January 2020 Accepted: 8 April 2020

Published online: 21 April 2020

## References

- Webster RG, Govorkova EA. Continuing challenges in influenza. *Ann N Y Acad Sci.* 2014;1323:115–39.
- Pica N, Palese P. Toward a universal influenza virus vaccine: prospects and challenges. *Annu Rev Med.* 2013;64:189–202.
- Krammer F, Palese P. Advances in the development of influenza virus vaccines. *Nat Rev Drug Discov.* 2015;14:167–82.
- Nachbagauer R, Krammer F. Universal influenza virus vaccines and therapeutic antibodies. *Clin Microbiol Infect.* 2017;23:222–8.
- Houser K, Subbarao K. Influenza vaccines: challenges and solutions. *Cell Host Microbe.* 2015;17:295–300.
- Tatullian SA, Tamm LK. Secondary structure, orientation, oligomerization, and lipid interactions of the transmembrane domain of influenza hemagglutinin. *Biochemistry.* 2000;39:496–507.
- Bouvier NM, Palese P. The biology of influenza viruses. *Vaccine.* 2008; 26(Suppl 4):D49–53.
- Chang DK, Cheng SF, Kantchev EA, Lin CH, Liu YT. Membrane interaction and structure of the transmembrane domain of influenza hemagglutinin and its fusion peptide complex. *BMC Biol.* 2008;6:2.
- Kim SM, Kim YI, Park SJ, Kim EH, Kwon HI, Si YJ, Lee IW, Song MS, Choi YK. Vaccine efficacy of inactivated, chimeric Hemagglutinin H9/H5N2 avian influenza virus and its suitability for the marker vaccine strategy. *J Virol.* 2017;91(6). <https://doi.org/10.1128/JVI.01693-16>.
- Zhang Y, Xu C, Zhang H, Liu GD, Xue C, Cao Y. Targeting Hemagglutinin: approaches for broad protection against the influenza A virus. *Viruses.* 2019; 11(5). <https://doi.org/10.3390/v11050405>.
- Wrarmert J, Koutsonanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. *J Exp Med.* 2011;208:181–93.
- Krammer F, Palese P. Influenza virus hemagglutinin stalk-based antibodies and vaccines. *Curr Opin Virol.* 2013;3:521–30.
- Mineev KS, Lyukmanova EN, Krabben L, Serebryakova MV, Shulepko MA, Arseniev AS, Kordiyukova LV, Veit M. Structural investigation of influenza

- virus hemagglutinin membrane-anchoring peptide. *Protein Eng Des Sel*. 2013;26:547–52.
14. Xu S, Zhou J, Liu K, Liu Q, Xue C, Li X, Zheng J, Luo D, Cao Y. Mutations of two transmembrane cysteines of hemagglutinin (HA) from influenza A H3N2 virus affect HA thermal stability and fusion activity. *Virus Genes*. 2013;47:20–6.
  15. Xu S, Zhou J, Liu Q, Liu K, Xue C, Li X, Zheng J, Luo D, Cao Y. Evidences for the existence of intermolecular disulfide-bonded oligomers in the H3 hemagglutinins expressed in insect cells. *Virus Genes*. 2014;48:304–11.
  16. Liu Q, Liu K, Xue C, Zhou J, Li X, Luo D, Zheng J, Xu S, Liu GD, Cao Y. Recombinant influenza H1, H5 and H9 hemagglutinins containing replaced H3 hemagglutinin transmembrane domain showed enhanced heterosubtypic protection in mice. *Vaccine*. 2014;32:3041–9.
  17. Zhou J, Xu S, Ma J, Lei W, Liu K, Liu Q, Ren Y, Xue C, Cao Y. Recombinant influenza A H3N2 viruses with mutations of HA transmembrane cysteines exhibited altered virological characteristics. *Virus Genes*. 2014;48:273–82.
  18. Liu Q, Xue C, Zheng J, Liu K, Wang Y, Wei Y, Liu GD, Cao Y. Influenza bivalent vaccine comprising recombinant H3 hemagglutinin (HA) and H1 HA containing replaced H3 hemagglutinin transmembrane domain exhibited improved heterosubtypic protection immunity in mice. *Vaccine*. 2015;33:4035–40.
  19. Wang Y, Wu J, Xue C, Wu Z, Lin Y, Wei Y, Wei X, Qin J, Zhang Y, Wen Z, et al. A recombinant H7N9 influenza vaccine with the H7 hemagglutinin transmembrane domain replaced by the H3 domain induces increased cross-reactive antibodies and improved interclade protection in mice. *Antivir Res*. 2017;143:97–105.
  20. Wang Y, Zhang Y, Wu J, Lin Y, Wu Z, Wei Y, Wei X, Qin J, Xue C, Liu GD, Cao Y. Recombinant influenza H7 hemagglutinin containing CFLC minidomain in the transmembrane domain showed enhanced cross-protection in mice. *Virus Res*. 2017;242:16–23.
  21. Qin J, Zhang Y, Shen X, Gong L, Peng O, Liu Y, Xue C, Cao Y. H7 virus-like particles assembled by hemagglutinin containing H3N2 transmembrane domain and M1 induce broad homologous and heterologous protection in mice. *Vaccine*. 2018;36:5030–6.
  22. Qin J, Zhang Y, Shen X, Gong L, Xue C, Cao Y. Biological characteristics and immunological properties in Muscovy ducks of H5N6 virus-like particles composed of HA-TM/HA-TMH3 and M1. *Avian Pathol*. 2019;48:35–44.
  23. Braakman I, Bulleid NJ. Protein folding and modification in the mammalian endoplasmic reticulum. *Annu Rev Biochem*. 2011;80:71–99.
  24. Gruber CW, Cemazar M, Heras B, Martin JL, Craik DJ. Protein disulfide isomerase: the structure of oxidative folding. *Trends Biochem Sci*. 2006;31:455–64.
  25. Hatahet F, Ruddock LW. Protein disulfide isomerase: a critical evaluation of its function in disulfide bond formation. *Antioxid Redox Signal*. 2009;11:2807–50.
  26. Freedman RB, Desmond JL, Byrne LJ, Heal JW, Howard MJ, Sanghera N, Walker KL, Wallis AK, Wells SA, Williamson RA, Romer RA. 'Something in the way she moves': the functional significance of flexibility in the multiple roles of protein disulfide isomerase (PDI). *Biochim Biophys Acta*. 1865;2017:1383–94.
  27. Ni M, Lee AS. ER chaperones in mammalian development and human diseases. *FEBS Lett*. 2007;581:3641–51.
  28. Vandenbroeck K, Martens E, Alloza I. Multi-chaperone complexes regulate the folding of interferon-gamma in the endoplasmic reticulum. *Cytokine*. 2006;33:264–73.
  29. Hettinghouse A, Liu R, Liu CJ. Multifunctional molecule ERp57: from cancer to neurodegenerative diseases. *Pharmacol Ther*. 2018;181:34–48.
  30. Solda T, Garbi N, Hammerling GJ, Molinari M. Consequences of ERp57 deletion on oxidative folding of obligate and facultative clients of the calnexin cycle. *J Biol Chem*. 2006;281:6219–26.
  31. Wang K, Holtz KM, Anderson K, Chubet R, Mahmoud W, Cox MM. Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccine. *Vaccine*. 2006;24:2176–85.
  32. Kang SM, Guo L, Yao Q, Skountzou I, Compans RW. Intranasal immunization with inactivated influenza virus enhances immune responses to coadministered simian-human immunodeficiency virus-like particle antigens. *J Virol*. 2004;78:9624–32.
  33. Treanor JJ. Prospects for broadly protective influenza vaccines. *Am J Prev Med*. 2015;49:S355–63.
  34. Weldon WC, Wang BZ, Martin MP, Koutsouanos DG, Skountzou I, Compans RW. Enhanced immunogenicity of stabilized trimeric soluble influenza hemagglutinin. *PLoS One*. 2010;5(9). <https://doi.org/10.1371/journal.pone.0012466>.
  35. Wohlbold TJ, Nachbagauer R, Margine I, Tan GS, Hirsh A, Krammer F. Vaccination with soluble headless hemagglutinin protects mice from challenge with divergent influenza viruses. *Vaccine*. 2015;33:3314–21.
  36. Victor BL, Baptista AM, Soares CM. Structural determinants for the membrane insertion of the transmembrane peptide of hemagglutinin from influenza virus. *J Chem Inf Model*. 2012;52:3001–12.
  37. Doms RW, Helenius A. Quaternary structure of influenza virus hemagglutinin after acid treatment. *J Virol*. 1986;60:833–9.
  38. Gamblin SJ, Skehel JJ. Influenza hemagglutinin and neuraminidase membrane glycoproteins. *J Biol Chem*. 2010;285:28403–9.
  39. Impagliazzo A, Milder F, Kuipers H, Wagner MV, Zhu X, Hoffman RM, van Meersbergen R, Huizingh J, Wanningen P, Verspuij J, et al. A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen. *Science*. 2015;349:1301–6.
  40. Kanekiyo M, Wei CJ, Yassine HM, McTamney PM, Boyington JC, Whittle JR, Rao SS, Kong WP, Wang L, Nabel GJ. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. *Nature*. 2013;499:102–6.
  41. Wei CJ, Xu L, Kong WP, Shi W, Canis K, Stevens J, Yang ZY, Dell A, Haslam SM, Wilson IA, Nabel GJ. Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. *J Virol*. 2008;82:6200–8.

## Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Ready to submit your research? Choose BMC and benefit from:**

- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

**At BMC, research is always in progress.**

Learn more [biomedcentral.com/submissions](https://biomedcentral.com/submissions)

